Comparative Pharmacology
Head-to-head clinical analysis: EPIVIR versus STAVZOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIVIR versus STAVZOR.
EPIVIR vs STAVZOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to lamivudine triphosphate, which competes with endogenous deoxycytidine triphosphate for incorporation into viral DNA by HIV reverse transcriptase and hepatitis B virus polymerase, resulting in DNA chain termination.
Stavudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to stavudine triphosphate, which competes with natural substrate deoxythymidine triphosphate and inhibits HIV-1 reverse transcriptase by incorporating into viral DNA, causing chain termination.
300 mg orally once daily or 150 mg orally twice daily
300 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 5 to 7 hours in adults with normal renal function. In neonates, half-life is prolonged (up to 12-18 hours). Clinically, dosing interval adjustments are required for creatinine clearance <30 mL/min.
Terminal elimination half-life is approximately 1.0-1.6 hours in adults with normal renal function. In patients with renal impairment, half-life is prolonged (up to 8-14 hours with creatinine clearance <10 mL/min), requiring dose adjustment. Intracellular (active triphosphate) half-life is 3.5-7 hours.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with active tubular secretion contributing significantly. Biliary/fecal elimination is minimal (<10%).
Stavudine is eliminated primarily by renal excretion (approximately 40% of an administered dose is recovered unchanged in urine within 6 hours, with up to 60-70% overall) and to a lesser extent by fecal excretion (approximately 30%). Active tubular secretion contributes to renal elimination.
Category C
Category C
NRTI Antiretroviral
NRTI Antiretroviral